Bariatric surgery causes high rates of remission of type 2 diabetes; however, the mechanisms remain unresolved. A new study identifies cholic-acid-7-sulfate as a novel contributor to the metabolic benefits of bariatric surgery and an attractive target for treatment of type 2 diabetes.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Chaudhari, S. N. et al. Nat. Chem. Biol. https://doi.org/10.1038/s41589-020-0604-z (2020).
Pories, W. J. et al. Ann. Surg. 222, 339–352 (1995).
Ding, L. et al. Hepatology 64, 760–773 (2016).
McGavigan, A. K. et al. Gut 66, 226–234 (2017).
Ryan, K. K. et al. Nature 509, 183–188 (2014).
Thomas, C. et al. Cell Metab. 10, 167–177 (2009).
Vassileva, G. et al. Biochem. J. 398, 423–430 (2006).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The author declares no competing interests.
Rights and permissions
About this article
Cite this article
Cummings, B.P. Bariatric surgery works through a novel bile acid. Nat Chem Biol 17, 5–6 (2021). https://doi.org/10.1038/s41589-020-0648-0
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41589-020-0648-0